ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2805

Outcomes of Lupus Nephritis Patients Following Discontinuation of Treatment

Chee Ken Cheah1, Shirish Sangle (Joint First Author)1, Alina Casian2, Oier Barrutia1, Munther Khamashta1 and David D'Cruz1, 1Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom, 2Rheumatology, Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: immunosuppressants, Lupus nephritis, outcomes and treatment

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Lupus nephritis (LN) complicates 60% of systemic lupus erythematosus (SLE) patients within 5 years of diagnosis. Glucocorticoids and disease modifying immunosuppressive drugs (IS) are associated with adverse effects, treatment failure and relapses and treatment duration is uncertain. Our aims were to study long-term renal outcomes of LN patients who discontinued treatment after achieving disease remission and to identify predictors of renal relapse off IS therapy.

Methods: This was a retrospective cohort study of LN in our Lupus Clinic who discontinued IS treatment. Patient data was retrieved from October 1991 and through to 1stDecember 2015, or until their last follow-up date. Renal relapse was defined as raised urine protein-creatinine ratio (UPCR) of ≥ 50mg/mmol or ≥50mg/mmol from baseline (equivalent to proteinuria 0.5g/L), or with renal biopsy proven recurrence of nephritis. Predictive factors for renal relapse were identified using logistic regression model. Data analysis was performed using SPSS Version 23.0.

Results: 43 patients were identified, 25 (58%) had sufficient data for analysis. 60% were Caucasians, 28% of Afro-Caribbean origin and 12% were Asian. 23 patients (92%) were female. Mean age at LN diagnosis was 33.5 ± 11.4 years. 7 had class IV and 7 had class V LN (28% for each group). The remaining patients had class III LN (16%), class III/IV LN (12%), and class II LN (8%). An association with anti phospholipid syndrome (APS) was found in 28% and 7 with positive aPL antibodies that remained asymptomatic. Mean duration of LN treatment was 5.6±4.2years. 17 patients (68%) received IV cyclophosphamide (CYC) as induction therapy. Azathioprine was the commonest maintenance agent (76%). Most received hydroxychloroquine throughout maintenance phase (76%). At the time of treatment discontinuation, mean eGFR was 87.7± 21.87 ml/1.73m2/min. Mean serum albumin was 41.3± 3.88 mmol/L and mean UPCR was 59.0± 85.11 mg/mmol. Anti- dsDNA antibodies persisted in 24% of the cohort. Despite discontinuation, 80% remained under active surveillance. Only 4 patients lost to follow-up. There was 1 death with cause unknown. Renal relapses were recorded in 7 patients (28%) and 1 patient developed non-renal flare. Mean time to event estimated at 47.2months (95% CI: 36.7,57.7). None developed end-stage renal disease after treatment discontinuation. Young age at LN diagnosis, low C3/C4, high UPCR, low eGFR upon discontinuation of treatment and ethnicity were six predictors of possible renal relapse. Our fitted model was statistically significant, χ2=18.22, p=0.011 and correctly classified 88% of cases.

Conclusion: Our long-term LN relapse rates after discontinuation of treatment are similar to previous studies. Nevertheless, reliable comparisons are limited by the retrospective nature of our study. It is possible to discontinue treatment for LN but the optimal duration of IS therapy remains uncertain and randomized clinical trials of treatment withdrawal are warranted.


Disclosure: C. K. Cheah, None; S. Sangle (Joint First Author), None; A. Casian, None; O. Barrutia, None; M. Khamashta, None; D. D'Cruz, AstraZeneca, 5,Eli Lilly and Company, 5,GlaxoSmithKline, 5,Roche Pharmaceuticals, 5.

To cite this abstract in AMA style:

Cheah CK, Sangle (Joint First Author) S, Casian A, Barrutia O, Khamashta M, D'Cruz D. Outcomes of Lupus Nephritis Patients Following Discontinuation of Treatment [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/outcomes-of-lupus-nephritis-patients-following-discontinuation-of-treatment/. Accessed February 25, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/outcomes-of-lupus-nephritis-patients-following-discontinuation-of-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.